Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Danicamtiv · MYK-491, SAR-440181

Small molecule · developed by Kardigan

Phase 3 Most advanced trial

KARD Developer

1 Registered trials

What is Danicamtiv?

Danicamtiv is an agent studied in symptomatic genetic dilated cardiomyopathy, administered twice daily.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MYK-491, SAR-440181
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Kardigan, Inc. (KARD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 7B2CS922HI

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07771465	Phase 3	Symptomatic Genetic Dilated Cardiomyopathy (DCM)	Recruiting	KARD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Symptomatic Genetic Dilated Cardiomyopathy (DCM)

More from Kardigan

Ataciguat Phase 2/3 Tonlamarsen Phase 2

Sources

ClinicalTrials.gov NCT07771465

Updated Oct 11, 2026. Something wrong or missing? Report it on the KARD page.

Follow KARD, the company behind Danicamtiv

See KARD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KARD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z